By Vlad Schepkov
Investing.com -- Here is your weekly Pro Recap preview of key biotech and FDA catalysts to look out for in the next week: PDUFA reviews for Eyenovia and Protalix, an earnings release and Phase 1 results for Seres Therapeutics, and an FDA vote for Sarepta Therapeutics and Roche.
Eyenovia set for a review of its pupil dilation treatment
On Monday, make sure to watch Eyenovia (NASDAQ: EYEN ), which is set for PDUFA review of MydCombi - the company's drug candidate for treatment of pupil dilation (mydriasis).
Keep in mind the drug previously received a Complete Response Letter (CRL) from the FDA back in October 2021, although investors are definitely excited for a potential green light this time around: Shares are up nearly 170% year to date.
Wall Street analysts have a positive view of the stock, as well: 5 buy ratings, 1 hold, and 0 sells.
Another day, another PDUFA. On the docket for Tuesday is a PDUFA review for Protalix Biotherapeutics' (NYSE: PLX ) PRX-102 compound, its Fabry disease candidate - news that InvestingPro subscribers will get in rapid fire.
Protalix likewise got a CRL back in April 2021 and also appears to have regained some trust among investors ahead of the key decision: Shares have gained just shy of 140% since the start of the year.
The company has 3 buy ratings from analysts, 5 holds, and 0 sells ahead of the decision.
Seres Therapeutics (NASDAQ: MCRB ) has scheduled its Q1 earnings release and conference call for Tuesday before the market opens.
The company is also set to announce initial Phase 1b Cohort 1 safety and pharmacology data for SER-155, its investigational drug for treatment of gastrointestinal infections, bacteremia, and GvHD (graft versus host disease).
The stock sports 12 Buys, 1 Hold, and 2 Sells from analysts.
Sarepta Therapeutics and Roche
The companies are co-developing SRP-9001, a candidate to potentially treat Duchenne muscular dystrophy. The drug currently has an FDA Advisory Committee (AdCom) vote planned for Friday, with a PDUFA set some two and half weeks after that - on May 29.
Here's what a Morgan Stanley analyst had to say about the upcoming vote back in April:
We expect a supportive AdCom based on the evidence supporting the surrogate endpoint and continue to see the AdCom as an opportunity for mgt. to present their case publicly.
SRPT currently has 31 buys, 7 holds, and 1 sell across analysts.
Add Chart to Comment
We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
- Enrich the conversation
- Stay focused and on track. Only post material that’s relevant to the topic being discussed.
- Be respectful. Even negative opinions can be framed positively and diplomatically.
- Use standard writing style. Include punctuation and upper and lower cases.
- NOTE: Spam and/or promotional messages and links within a comment will be removed
- Avoid profanity, slander or personal attacks directed at an author or another user.
- Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
- Only English comments will be allowed.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.